Atara Biotherapeutics, Inc. (ATRA)
| Market Cap | 64.49M -34.9% |
| Revenue (ttm) | 3.97M -97.4% |
| Net Income | -14.61M |
| EPS | -1.01 |
| Shares Out | 10.19M |
| PE Ratio | n/a |
| Forward PE | 6.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,417 |
| Open | 6.25 |
| Previous Close | 6.34 |
| Day's Range | 6.25 - 6.86 |
| 52-Week Range | 3.92 - 19.15 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 13.67 (+115.96%) |
| Earnings Date | Nov 10, 2026 |
About ATRA
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. T... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ATRA stock is "Buy." The 12-month stock price target is $13.67, which is an increase of 115.96% from the latest price.
News
Atara Biotherapeutics files $200M mixed securities shelf
17:01 EST Atara Biotherapeutics (ATRA) files $200M mixed securities shelf
Atara Biotherapeutics reports Q3 EPS (15c), consensus (22c)
Reports Q3 revenue $1.2M, consensus $0.5M. āThe resubmission of the tab-cel BLA was an important milestone this quarter, and we remain focused on supporting Pierre Fabre Pharmaceuticals (PFP) toward a...
Atara Biotherapeutics says cash sufficient to fund operations into mid-2027
The company stats: āOperating expenses are expected to decline significantly year-over-year, reflecting the full-year benefit of cost-reduction initiatives implemented in 2025 and the first half of 20...
Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Earnings release: Q3 2026
Atara Biotherapeutics released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Atara Biotherapeutics Quarterly report: Q3 2026
Atara Biotherapeutics has published its Q3 2026 quarterly earnings report on November 10, 2026.
Atara Biotherapeutics Registration statement: Registration filing
Atara Biotherapeutics filed a registration statement on November 10, 2026, providing details about a securities offering with the SEC.
Atara partner receives acceptance by FDA of BLA resubmission for tabelecleucel
Atara Biotherapeutics (ATRA) announced that its partner, Pierre Fabre Pharmaceuticals, PFP, has received acceptance by the U.S. Food and Drug Administration, FDA, of the Biologics License Application,...
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-celĀ®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara reports resubmission of tabelecleucel BLA to FDA
Atara Biotherapeutics (ATRA) provided an update that its partner, Pierre Fabre Pharmaceuticals, has resubmitted the tabelecleucel Biologics License Application to the U.S. Food and Drug Administration...
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics reports Q2 EPS (32c), consensus (32c)
Reports Q2 revenue $600K, consensus $366.67K. As previously communicated, PFP has indicated they intend to submit an updated dataset with additional patients and longer follow-up from the pivotal Phas...
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Quarterly report: Q2 2026
Atara Biotherapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Atara Biotherapeutics Earnings release: Q2 2026
Atara Biotherapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Atara Biotherapeutics Announces Changes to Its Board of Directors
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient h...
Atara Biotherapeutics Transcript: AGM 2026
The meeting covered board introductions, four key proposals, and voting procedures. All proposalsāincluding director elections, executive compensation, equity plan amendment, and auditor ratificationāwere approved, with final results to be filed in a Form 8-K.
Atara Biotherapeutics upgraded to Hold from Sell at Freedom Broker
Freedom Broker upgraded Atara Biotherapeutics (ATRA) to Hold from Sell with a price target of $10, up from $4. The FDA meeting between Pierre Fabre and the FDA ended onā¦
Atara Biotherapeutics reports Q1 EPS -29c, consensus -22c
Reports cash, cash equivalents and short-term investments as of March 31 totaled $8.4M as compared to $8.5M as of December 31, 2025. The company said, āAs previously communicated, Pierre Fabreā¦
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Quarterly report: Q1 2026
Atara Biotherapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Atara Biotherapeutics Earnings release: Q1 2026
Atara Biotherapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Atara Biotherapeutics upgraded to Buy from Hold at Canaccord
Canaccord upgraded Atara Biotherapeutics (ATRA) to Buy from Hold with a price target of $13, up from $6. The type-A meeting with the FDA provides a potential approval pathway forā¦
Atara Biotherapeutics trading halted, volatility trading pause
10:50 EDT Atara Biotherapeutics (ATRA) trading halted, volatility trading pause